Non-benign neoplasms

1 paper1 finding

Human trial1

Associations

1

Fezolinetant

upin humans1RR 6.6

1 study

Fezolinetant is associated with non-benign neoplasms in humans (RR 6.6 (95% CI 0.9–51.3)).
“giving a relative risk at the licensed dose of 6.6 (95% confidence interval 0.9-51.3)”
ReviewLicensed-dose comparison with placebo in the SKYLIGHT phase III programme45 mg
Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance
Drug safety14 Oct 2026

More on Fezolinetant

Latest

1 in 12 months

Drug Safety5 h

Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance

Trial in peopleNeoplasm